J&J Likely to Raise Vaccine Prices Next Year

Jul.21 — Johnson & Johnson CFO Joseph Wolk discusses the efficacy of the company’s Covid-19 vaccine against the delta variant, second-quarter results, and efforts to address damage claims over its talcum-based baby powder. He speaks on “Bloomberg Markets.”